Uma N Rao1, Laurie E McLouth2, Yue Zheng3, Stephanie Smith4, F Stephen Hodi3,5, Gary I Cohen6, Thomas T Amatruda7, Shaker R Dakhil8, Brendan D Curti9, Ibrahim Nakhoul10, Sreenivasa R Chandana11, Charles L Bane12, David E Marinier13, Sandra J Lee3, Vernon K Sondak14, John M Kirkwood1, Ahmad A Tarhini14, Lynne I Wagner15. 1. University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. 2. Department of Behavioral Science, College of Medicine, Markey Cancer Center, University of Kentucky, 467 Healthy Kentucky Research Building, 760 Press Avenue, Lexington, KY, 40508, USA. Laurie.mclouth@uky.edu. 3. Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, USA. 4. Nancy N. and J.C. Lewis Cancer and Research Pavilion, St. Joseph's/Candler, Savannah, GA, USA. 5. Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, USA. 6. Greater Baltimore Medical Center, Baltimore, MD, USA. 7. Minnesota Oncology, Fridley, MN, USA. 8. Ascension Via Christi Hospitals, Wichita, KS, USA. 9. Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. 10. Regional Cancer Center at Indian Path Community Hospital, Kingsport, TN, USA. 11. Cancer and Hematology Centers of Western Michigan/Cancer Research Consortium of West Michigan NCORP, Grand Rapids, MI, USA. 12. Good Samaritan Hospital-Dayton, Dayton, OH, USA. 13. Gundersen Health System, La Crosse, WI, USA. 14. Moffitt Cancer Center, Tampa, FL, USA. 15. Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
Abstract
PURPOSE: Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we compared health-related quality of life (HRQoL), gastrointestinal (GI), and treatment-specific physical and cognitive/emotional symptoms. We also compared treatment-specific concerns between all arms. METHODS: We assessed HRQoL using the Functional Assessment of Cancer Therapy-General, physical and cognitive/emotional concerns using the FACT-Biologic Response Modifier subscale, and GI symptoms with the Functional Assessment of Chronic Illness Therapy-Diarrhea subscale pre-treatment and every 3 months. The primary outcome was the difference in HRQoL at 3 months between ipi3/ipi10 vs. HDI. RESULTS: 549 patients (n = 158 ipi3; n = 191 ipi10; n = 200 HDI) were analyzed. 3-month completion was 58.7%. Compared to HDI, ipilimumab patients reported better HRQoL (ipi3 = 87.5 ± 14.6 vs. HDI = 74.7 ± 15.4, p < .001; ipi10 = 84.9 ± 16.5 vs. HDI, p < .001) and fewer physical (ipi3 = 22.3 ± 4.6 vs. HDI = 17.1 ± 5.4, p < .001; ipi10 = 21.8 ± 5.0 vs. HDI p < .001) and cognitive/emotional (ipi3 = 18.6 ± 4.4 vs. HDI = 15.0 ± 5.3, p < .001; ipi10 = 17.7 ± 4.8 vs. HDI p < .001) concerns, but worse GI symptoms (ipi3 = 40.8 ± 5.0 vs. HDI = 42.2 ± 2.9, p = .011; ipi10 = 39.5 ± 7.0 vs. HDI, p < .001). Fewer ipilimumab patients reported worsening treatment-specific concerns (e.g., 52% of ipi3 and 58% of ipi10 reported worsening fatigue vs. 82% HDI, p's < .001). CONCLUSION: PROs demonstrated less toxicity of ipi3 compared to HDI and ipi10. Priorities for symptom management among patients receiving ipilimumab include GI toxicities, fatigue, weakness, appetite loss, arthralgia, and depression. TRIAL REGISTRATION: NCT01274338, January 11, 2011 (first posted date) https://clinicaltrials.gov/ct2/show/NCT01274338?term=NCT01274338&draw=2&rank=1 .
PURPOSE: Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we compared health-related quality of life (HRQoL), gastrointestinal (GI), and treatment-specific physical and cognitive/emotional symptoms. We also compared treatment-specific concerns between all arms. METHODS: We assessed HRQoL using the Functional Assessment of Cancer Therapy-General, physical and cognitive/emotional concerns using the FACT-Biologic Response Modifier subscale, and GI symptoms with the Functional Assessment of Chronic Illness Therapy-Diarrhea subscale pre-treatment and every 3 months. The primary outcome was the difference in HRQoL at 3 months between ipi3/ipi10 vs. HDI. RESULTS: 549 patients (n = 158 ipi3; n = 191 ipi10; n = 200 HDI) were analyzed. 3-month completion was 58.7%. Compared to HDI, ipilimumab patients reported better HRQoL (ipi3 = 87.5 ± 14.6 vs. HDI = 74.7 ± 15.4, p < .001; ipi10 = 84.9 ± 16.5 vs. HDI, p < .001) and fewer physical (ipi3 = 22.3 ± 4.6 vs. HDI = 17.1 ± 5.4, p < .001; ipi10 = 21.8 ± 5.0 vs. HDI p < .001) and cognitive/emotional (ipi3 = 18.6 ± 4.4 vs. HDI = 15.0 ± 5.3, p < .001; ipi10 = 17.7 ± 4.8 vs. HDI p < .001) concerns, but worse GI symptoms (ipi3 = 40.8 ± 5.0 vs. HDI = 42.2 ± 2.9, p = .011; ipi10 = 39.5 ± 7.0 vs. HDI, p < .001). Fewer ipilimumab patients reported worsening treatment-specific concerns (e.g., 52% of ipi3 and 58% of ipi10 reported worsening fatigue vs. 82% HDI, p's < .001). CONCLUSION: PROs demonstrated less toxicity of ipi3 compared to HDI and ipi10. Priorities for symptom management among patients receiving ipilimumab include GI toxicities, fatigue, weakness, appetite loss, arthralgia, and depression. TRIAL REGISTRATION: NCT01274338, January 11, 2011 (first posted date) https://clinicaltrials.gov/ct2/show/NCT01274338?term=NCT01274338&draw=2&rank=1 .
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: J M Kirkwood; J Ibrahim; D H Lawson; M B Atkins; S S Agarwala; K Collins; R Mascari; D M Morrissey; P B Chapman Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: S J O'Day; M Maio; V Chiarion-Sileni; T F Gajewski; H Pehamberger; I N Bondarenko; P Queirolo; L Lundgren; S Mikhailov; L Roman; C Verschraegen; R Humphrey; R Ibrahim; V de Pril; A Hoos; J D Wolchok Journal: Ann Oncol Date: 2010-02-10 Impact factor: 32.976
Authors: Caroline Robert; Jean J Grob; Daniil Stroyakovskiy; Boguslawa Karaszewska; Axel Hauschild; Evgeny Levchenko; Vanna Chiarion Sileni; Jacob Schachter; Claus Garbe; Igor Bondarenko; Helen Gogas; Mario Mandalá; John B A G Haanen; Celeste Lebbé; Andrzej Mackiewicz; Piotr Rutkowski; Paul D Nathan; Antoni Ribas; Michael A Davies; Keith T Flaherty; Paul Burgess; Monique Tan; Eduard Gasal; Maurizio Voi; Dirk Schadendorf; Georgina V Long Journal: N Engl J Med Date: 2019-06-04 Impact factor: 91.245
Authors: J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: J M Kirkwood; J G Ibrahim; J A Sosman; V K Sondak; S S Agarwala; M S Ernstoff; U Rao Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: Jeffrey Weber; John A Thompson; Omid Hamid; David Minor; Asim Amin; Ilan Ron; Ruggero Ridolfi; Hazem Assi; Anthony Maraveyas; David Berman; Jonathan Siegel; Steven J O'Day Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245
Authors: Ahmad A Tarhini; Sandra J Lee; F Stephen Hodi; Uma N M Rao; Gary I Cohen; Omid Hamid; Laura F Hutchins; Jeffrey A Sosman; Harriett M Kluger; Zeynep Eroglu; Henry B Koon; Donald P Lawrence; Kari L Kendra; David R Minor; Carrie B Lee; Mark R Albertini; Lawrence E Flaherty; Teresa M Petrella; Howard Streicher; Vernon K Sondak; John M Kirkwood Journal: J Clin Oncol Date: 2019-12-27 Impact factor: 50.717